Professor, Medicine, University of Minnesota Medical School
Pulmonology
Dr. Peter B. Bitterman, MD
|
|
Give Review
Peter Bitterman practices Pulmonology. He went to medical school at Yale University School of Medicine. Yale University School of Medicine is one of the top medical schools in the US. Yale University School of Medicine is ranked 7/57 in Research/PrimaryCare. He has 2 awards "CMS Meaningful Use Stage 1 Certification" and "Elected Member". Peter Bitterman is also published. He has 40 publications published. The lastest publication: "Pathologic Regulation of Collagen I by an Aberrant PP2A/HDAC4/miR-29 Signal Axis in IPF Fibroblasts.' He accepts Medicare.
Publications
- Pathologic Regulation of Collagen I by an Aberrant PP2A/HDAC4/miR-29 Signal Axis in IPF Fibroblasts.
- eIF4E Threshold Levels Differ in Governing Normal and Neoplastic Expansion of Mammary Stem and Luminal Progenitor Cells.
- eIF4E-mediated translational control of Cancer incidence.
- Reemergence of Hedgehog Mediates Epithelial-mesenchymal Crosstalk in Pulmonary Fibrosis.
- miR-210 Promotes IPF Fibroblast Proliferation in Response to Hypoxia.
- Small-molecule inhibition of oncogenic eukaryotic protein translation in mesothelioma cells.
- Identification of a Cell-of-Origin for Fibroblasts Comprising the Fibrotic Reticulum in Idiopathic Pulmonary Fibrosis.
- Double Stranded RNA-Dependent Protein Kinase Deficiency Protects the Heart from Systolic Overload-Induced Congestive Heart Failure.
- Future Directions in Idiopathic Pulmonary Fibrosis Research: An NHLBI Workshop Report.
- Protein Expression Profile of Rat Type Two Alveolar Epithelial Cells During Hyperoxic Stress and Recovery.
- Telomerase and Telomere Length in Pulmonary Fibrosis.
- Treatment of Breast and Lung Cancer Cells with a N-7 Benzyl Guanosine Monophosphate Tryptamine Phosphoramidate Pronucleotide (4Ei-1) Results in Chemosensitization to G...
- Regulation of myofibroblast differentiation by poly(ADP-ribose) polymerase 1.
- Molecular targeted therapy in Lung cancer.
- Cap-dependent mRNA translation and the ubiquitin-proteasome system cooperate to promote ERBB2-dependent esophageal Cancer phenotype.
- Cap-Dependent Translation Initiation Factor eIF4E: An Emerging AntiCancer Drug Target.
- Novel role of c-jun N-terminal kinase in regulating the initiation of cap-dependent translation.
- Cell Plasticity in Lung injury and repair: report from an NHLBI workshop, April 19-20, 2010.
- Genome-wide analysis of translationally regulated genes in hypoxic alveolar epithelial cells.
- Non-ATG-initiated translation directed by microsatellite expansions.
- Eukaryotic initiation factor 4E binding protein family of proteins: sentinels at a translational control checkpoint in Lung tumor defense.
- Regulatory element identification in subsets of transcripts: comparison and integration of current computational methods.
- Nontoxic chemical interdiction of the epithelial-to-mesenchymal transition by targeting cap-dependent translation.
- Expression, purification and characterization of recombinant mouse translation initiation factor eIF4E as a dihydrofolate reductase (DHFR) fusion protein.
- Conserved GU-rich elements mediate mRNA decay by binding to CUG-binding protein 1.
- Fibrotic myofibroblasts manifest genome-wide derangements of translational control.
- Histone deacetylase inhibitors suppress TF-kappaB-dependent agonist-driven tissue factor expression in endothelial cells and monocytes.
- Akt-mediated liver growth promotes induction of cyclin E through a novel translational mechanism and a p21-mediated cell cycle arrest.
- Eukaryotic translation initiation factor 4E induced progression of primary human mammary epithelial cells along the Cancer pathway is associated with targeted translat...
- Repression of cap-dependent translation attenuates the transformed phenotype in non-small cell Lung cancer both in vitro and in vivo.
- The cap-dependent translation apparatus integrates and amplifies Cancer pathways.
- Activation of translation complex eIF4F is essential for the genesis and maintenance of the malignant phenotype in human mammary epithelial cells.
- Translation initiation factor 4E blocks endoplasmic reticulum-mediated apoptosis.
- Molecular targets in drugs discovery in idiopathic Pulmonary fibrosis. Work in progress.
- Translation factor eIF4E rescues cells from Myc-dependent apoptosis by inhibiting cytochrome c release.
- Mechanisms of cytokine induced NO-mediated cardiac fibroblast apoptosis.
- Future research directions in idiopathic Pulmonary fibrosis: summary of a National Heart, Lung, and Blood Institute working group.
- Translational control of cell fate: availability of phosphorylation sites on translational repressor 4E-BP1 governs its proapoptotic potency.
- Proteomic profiles in acute Respiratory distress syndrome differentiates survivors from non-survivors.
Schools
Yale University School Of Medicine
University of Chicago
NIH
Procedures Preformed
- Bronchoscopy
- Thoracentesis
- Ventilation Management
Conditions Treated
- Acidosis
- Asbestosis
- Asthma
- Atelectasis
- View All
Doctors Specialties
- Critical Care Medicine
- Pulmonology
Accepted Insurances
Awards
- CMS Meaningful Use Stage 1 Certification
- Elected Member
Education
-
University of Chicago -
Yale University School of Medicine
Hospital
-
University of Minnesota Medical Center, Fairview
Drug Facts
| NPI NUMBER | 1912943275 | |
| NPPES Provider LastName | BITTERMAN | |
| NPPES Provider FirstName | PETER | |
| NPPES Provider ZIPCode | 55455 | |
| NPPES Provider State | MN | |
| Specialty Description | Internal Medicine | |
| Total Claim Count | 29.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1912943275 |
| Last Name Of The Provider | BITTERMAN |
| First Name Of The Provider | PETER |
| View All |
Similar Doctors
|
|
Dr. Marshall I. Hertz, MD
 This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Susan L. Burton, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Kara J. Johnson, MD |
|
|
Dr. David H. Ingbar, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. William A. Marinelli, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Hyun J. Kim, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ramiro Saavedra Romero, MD |
|
|
Dr. Christopher T. Wall, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Michael I. Neren, MD |
|
|
Dr. David D. Miller, MD |
|
|
Dr. Jonathan D. Shelver, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. David M. Williams, DO |
|
|
Dr. Joshua S. Huelster, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Sandra J. Lynch |
|
|
Dr. Michael H. Wall, MD
This Doctor is OpenDoctor Recommended.
|